ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

migalastat

Also written as “Lucerastat”, “migalastat HCl” and “migalastat HCl 150 mg”.

Its studies are mostly in Fabry Disease, led by 2 companies.

Drug pageMigalastat: every studyAll 24 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 19, 200924 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioMarin Pharmaceuticalits history only172 open or runningphase 3since Jun 19, 2009Sep 13, 2005Dec 31, 2026phase 3 · NCT04020055
Idorsia Pharmaceuticals71 open or runningphase 3since Jan 16, 2018Oct 24, 2016Feb 13, 2029phase 3 · NCT07778667

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Idorsia Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 24, 2016First studies: 2 phase 1 studies in Healthy SubjectsFirst studyNCT02944487, NCT02944474
  2. Dec 15, 2017Phase 1 study in Healthy SubjectsNCT03380455 · 14 enrolled · Germany
  3. Jan 16, 2018Phase 3 study in Fabry DiseaseNCT03425539 · 118 enrolled · United States, Australia, Austria and more
  4. Nov 6, 2018Phase 3 study in Fabry DiseaseNCT03737214 · 107 enrolled · United States, Australia, Austria and more
  5. Feb 5, 2019Phase 1 study in HealthyNCT03832452 · 44 enrolled · Netherlands
  6. Aug 18, 2026Phase 3 study in Fabry DiseaseNCT07778667 · 16 planned · United States, Canada, France and more

Ahead

  1. Feb 13, 2029Primary completion: phase 3 study in Fabry DiseaseNCT07778667

TargetBeta

GLA →read by rule
“Alpha-galactosidase A stabiliser; Alpha-galactosidase A stabiliser”ChEMBL 37, by rule

Studies

All 7 Idorsia Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07778667Fabry Disease · United States, Canada, France and more3RecruitingFeb 13, 202916
NCT03832452Healthy · Netherlands1CompletedApr 22, 201944
NCT03737214Fabry Disease · United States, Australia, Austria and more3CompletedAug 31, 2026107
NCT03425539Fabry Disease · United States, Australia, Austria and more3CompletedAug 17, 2021118
NCT03380455Healthy Subjects · Germany1CompletedJan 29, 201814
NCT02944487Healthy Subjects · United Kingdom1CompletedDec 200239
NCT02944474Healthy Subjects · United Kingdom1CompletedMay 200437

How it is read

Names in the registry

  • “Lucerastat”, 6 entries
  • “migalastat HCl”, 5 entries
  • “migalastat HCl 150 mg”, 3 entries
  • “migalastat hydrochloride”, 3 entries
  • “Migalastat HCl 20 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.